| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA3921630
Max Phase: Preclinical
Molecular Formula: C18H17Cl2NO3
Molecular Weight: 366.24
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCOC(=O)c1cc(Cc2ccc(Cl)cc2Cl)c(=O)n2c1CCC2
Standard InChI: InChI=1S/C18H17Cl2NO3/c1-2-24-18(23)14-9-12(17(22)21-7-3-4-16(14)21)8-11-5-6-13(19)10-15(11)20/h5-6,9-10H,2-4,7-8H2,1H3
Standard InChI Key: HJHXJGLEEZYTSC-UHFFFAOYSA-N
Associated Targets(Human)
Phosphodiesterase 3 1749 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 366.24 | Molecular Weight (Monoisotopic): 365.0585 | AlogP: 3.87 | #Rotatable Bonds: 4 |
| Polar Surface Area: 48.30 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 3.84 | CX LogD: 3.84 |
| Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.77 | Np Likeness Score: -0.83 |
References
| 1. (2016) Indolizinone based derivatives as potential phosphodiesterase 3 (PDE3) inhibitors and a process for the preparation thereof, |
Source
Source(1):